Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Triptorelin | |
| Synonyms |
TRIPTORELIN 6-D-Tryptophan-LH-RH Triptorelin Detryptoreline triptorelin 6-D-Tryptophanluteinizing Hormone-releasing Factor AY-25650 AY25650 CL-118,532 CL118532 |
|
| Definitions |
A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1267 |
|
| Accepted_Therapeutic_Use_For |
Palliative treatment prostate carcinoma
|
|
| ALT_DEFINITION |
A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.
|
|
| CAS_Registry |
57773-63-4
|
|
| CHEBI_ID |
CHEBI:63633
|
|
| Chemical_Formula |
C64H82N18O13
|
|
| code |
C1267
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C192234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc OORO
|
|
| DEFINITION |
A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)
|
|
| Display_Name |
Triptorelin
|
|
| FDA_UNII_Code |
9081Y98W2V
|
|
| FULL_SYN |
TRIPTORELIN 6-D-Tryptophan-LH-RH Triptorelin Detryptoreline triptorelin 6-D-Tryptophanluteinizing Hormone-releasing Factor AY-25650 AY25650 CL-118,532 CL118532
|
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Triptorelin
|
|
| Legacy Concept Name |
Triptorelin
|
|
| Maps_To |
Triptorelin
|
|
| NCI_Drug_Dictionary_ID |
42944
|
|
| PDQ_Closed_Trial_Search_ID |
42944
|
|
| PDQ_Open_Trial_Search_ID |
42944
|
|
| Preferred_Name |
Triptorelin
|
|
| prefixIRI |
Thesaurus:C1267
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0077275
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |